Track topics on Twitter Track topics that are important to you
AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS).
The proposed mechanism of action of AUBAGIO is based on preclinical laboratory and animal model data.1 The exact mechanism by which AUBAGIO exerts its therapeutic effect in multiple sclerosis (MS) is not fully understood.2
Research supports that AUBAGIO inhibits the proliferation of stimulated T and B lymphocytes in the periphery, limiting overactivation of immune responses that can contribute to MS disease activity1-3
1 - Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011;124(2):75-84.
2 -Kieseier B, Kaplan J, Wiendl H. A proposed mechanism of action for teriflunomide in multiple sclerosis. Presented at European Charcot Foundation Symposium, 2012.
3 - Cherwinski HM, McCarley D, Schatzman R, Devens B, Ransom JT. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther. 1995;272:460-468.
4 - AUBAGIO (teriflunomide) [package insert]. Cambridge, MA: Genzyme Corporation; September 2012.
5 - Rückemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem. 1998;273:21682-21691.
For further information open - https://www.aubagio.com/